Neonc Technologies, Inc.

Senomyx, Inc.

University of Southern California

S&b Pharma, Inc.

Norac Pharma

Firmenich Incorporated

Vistagen Therapeutics, Inc.

Neone Technologies, Inc.

Daniel Levin

Thomas C Chen

Satish Puppali

Satish Pupalli

Peter Leeming

Donald Karanewsky

Catherine Tachdjian

Qing Chen

Xiao-Qing Tang

Tayyab Rashid

Daniel A Dickman

Emerich Eisenreich

James Luchi

Xiao Qing Tang

Xuejun Karl Liu

Satish Puppalli

Mackenzie Marrs

Donald S Karanewsky

Thomas Chen

The present invention provides for a perillyl alcohol (POH) carbamate, such as POH-Rolipram. The present invention also provides for a method of treating a disease such as cancer, by delivering to a patient a therapeutically effective amount of POH-Rolipram.

Pharmaceutical compositions comprising POH derivatives

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

Pharmaceutical compositions comprising monoterpenes

The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Pharmaceutical compositions comprising POH derivatives and methods of use

A pharmaceutical composition is provided which includes perillyl alcohol conjugated with a therapeutic agent and further includes and a hydrolyzable acylated aliphatic tail. A method of using the pharmaceutical composition is also provided for treating a condition or disease of a patient, e.g., cancer.

Pharmaceutical compositions comprising perillyl alcohol derivatives

The invention relates to an overall enantio-specific synthesis of 4-chlorokynurenine compounds, in particular L-4-chlorokynurenine, with improved yields. Large-scale syntheses are disclosed. The invention also relates to novel intermediates in the synthesis of L-4-chlorokynurenine.

Synthesis of 4-chlorokynurenines and intermediates

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (XI): wherein Y is C-Calkylene or C-Calkenylene; and Rand Rare independently C-Calkyl.

Processes and intermediates for making sweet taste enhancers

Crystalline Cannabidiol of a novel form, including (R,R)-(&#x2212;)-crystalline Cannabidiol, as well as methods of making such novel form of Cannabidiol, pharmaceutical formulations comprising such novel form of Cannabidiol, and methods of treating diseases with such novel form of Cannabidiol.

Crystalline form of cannabidiol

The present invention includes methods/processes and intermediates for preparing sulfamoyl chloride: 

The present invention includes methods/processes and intermediates for preparing compounds having structural Formula (I): wherein X is alkyl, substituted alkyl, alkenyl, substituted alkenyl, heteroalkyl, substituted heteroalkyl, heteroalkenyl, or substituted heteroalkenyl.

Growing community of inventors

La Canada, CA, United States of America

Daniel Levin